KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) EBT Margin (2016 - 2025)

Historic EBT Margin for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to 41.72%.

  • Vertex Pharmaceuticals' EBT Margin rose 27000.0% to 41.72% in Q4 2025 from the same period last year, while for Dec 2025 it was 38.69%, marking a year-over-year increase of 364300.0%. This contributed to the annual value of 38.69% for FY2025, which is 364300.0% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported EBT Margin of 41.72% as of Q4 2025, which was up 27000.0% from 42.22% recorded in Q3 2025.
  • Vertex Pharmaceuticals' 5-year EBT Margin high stood at 54.57% for Q3 2021, and its period low was 128.18% during Q2 2024.
  • For the 5-year period, Vertex Pharmaceuticals' EBT Margin averaged around 33.22%, with its median value being 44.84% (2022).
  • In the last 5 years, Vertex Pharmaceuticals' EBT Margin plummeted by -1747700bps in 2024 and then surged by 1714600bps in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' EBT Margin stood at 42.02% in 2021, then increased by 11bps to 46.76% in 2022, then fell by -3bps to 45.58% in 2023, then fell by -14bps to 39.03% in 2024, then grew by 7bps to 41.72% in 2025.
  • Its last three reported values are 41.72% in Q4 2025, 42.22% for Q3 2025, and 43.28% during Q2 2025.